Nomizo, T., Yamamoto, H., Murayama, T., Fukata, H., Nakamura, Y., Sonomura, M., Okuno, A., Kanda, N., Watanabe, C. and Kita, H. 2022. Immune-related adverse events caused by combined immune checkpoint inhibitor therapy with nivolumab and ipilimumab for lung cancer. Trends in Immunotherapy. 6, 1 (Jan. 2022). DOI:https://doi.org/10.24294/ti.v6.i1.1386.